



FOR IMMEDIATE RELEASE

Media Contact:

Allison Potter
p: 412.404.2677
e: allison@pascalecommunications.com

Company Contact:

Chris Calcaterra
p: 949.367.9600 ext. 226
e: ccalcaterra@glaukos.com

**Glaukos Corporation Named to *The Wall Street Journal's*
"The Next Big Thing" List
*Company Named Among the Top 50 Most Promising Venture-Backed Companies***

LAGUNA HILLS, CA, March 31, 2011 – Glaukos Corporation (Glaukos) has been named to *The Wall Street Journal's* "The Next Big Thing" list, which seeks to identify and rank venture-backed companies across all industries that have the capital, executive experience, and investor know-how to succeed. Glaukos, ranked number 19, was selected from a pool of more than 5,000 companies and ranked by proprietary data from Dow Jones VentureSource with input from Dow Jones VentureWire's reporters and editors.

"Venture capitalists are always looking for companies with a new idea that will prove powerful enough to explode into the marketplace," said Alan Murray, deputy managing editor of *The Wall Street Journal*. "'The Next Big Thing' highlights companies that we believe are worth watching and have a chance to make waves in their industry."

"It is humbling to be given such an accolade and named within this elite group of privately-held companies," says Thomas Burns, Chief Executive Officer of Glaukos Corporation. "This honor is testament to the strength of our management team and core technologies, the seasoning and track record of our Board of Directors, and our continued ability to raise venture capital to fund this business to help create this new glaucoma surgical marketplace."

Glaukos has raised \$126 million dollars to develop three generations of microstent devices to treat the full range of glaucoma disease. The company recently completed a \$29.5 million dollar raise led by Meritech Capital Partners.

"The Next Big Thing" is an annual ranking published by *The Wall Street Journal*. To be eligible for the ranking, a company must be based in the U.S., have raised an equity round of financing in the three years ended Nov. 30, 2010, and have a valuation of \$1 billion or less. The ranking was calculated by applying a set of four financial criteria: the track records of success for both a company's founders and management; track records for the investors on its board; the amount of capital raised in the last three years; and the percentage change in a company's valuation in the last year. Dow Jones VentureWire reporters and editors also provided their perspective and expertise beyond the numbers.

To view "The Next Big Thing" ranking, visit:

<http://online.wsj.com/article/SB10001424052748703300904576178673309577828.html>

-more-



About Dow Jones

Dow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, Web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron's, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision-making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company (www.dowjones.com) is a news corporation company (NASDAQ: NWS) (NASDAQ: NWSA) (ASX: NWS) (ASX: NWSLV) (www.newscorp.com).

About Glaukos Corporation

Glaukos Corporation is a privately-held ophthalmic company located in Laguna Hills, California, that is dedicated to researching and developing micro-technologies to improve glaucoma therapy. The company has developed a portfolio of microstent devices to treat glaucoma including the iStent® Trabecular Micro-Bypass stent, which is intended to re-establish natural physiological aqueous outflow and reduce intraocular pressure in open-angle glaucoma patients.

###